CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid) used for adults on a statin to reduce LDL-cholesterol. Esperion's season debut comes in the first race at Richmond this spring (March 31) on the No. 17 of Chris Buesc ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2023 was $34 million, representing a 79% increase year-over-year [61] - US net revenue was $20.3 million, a 45% increase year-over-year, driven by a 33% year-over-year increase in retail prescription equivalents [45] - Collaboration revenue, including combined royalty and partner revenue, was $13.7 million, an increase of approximately 174% year-over-year [54] - Cost of goods sold was $13.4 million, an increase of 106% year-over-year [13] - R&D expense was $14.9 million, a decrease of 49% year-over-year [13] - SG&A expense was $33.2 million, an increase of 33% year-over-year [55] - Cash equivalents and investment securities totaled $114.8 million as of September 30, 2023, down from $166.9 million on December 31, 2022 [62] Business Line Data and Key Metrics Changes - Retail prescription equivalents (RPE) grew 33% year-over-year and 8% quarter-over-quarter [11] - New-to-brand prescriptions grew 61% from March to September 2023 [46] - Weekly RPE trend remained above the 10,000 RPE mark, setting new weekly highs [53] Market Data and Key Metrics Changes - Three additional countries (Netherlands, Slovakia, and Spain) received approvals during Q3 2023 [12] - In Europe, 158,000 patients have been treated with the therapies, representing a sequential growth of 26% since May [60] Company Strategy and Development Direction - The company is focused on expanding its label to include cardiovascular risk reduction, which is seen as a significant growth catalyst [49] - A strategic collaboration with ACC and Amgen was announced to launch a cholesterol screening campaign [50] - The company anticipates a new label approval by March 31, 2024, which will significantly increase the addressable patient population [51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing litigation case and the potential for a positive ruling [20] - The company is preparing for the new label and expects to see accelerated prescription growth following the approval [49] - Management highlighted the importance of payer changes to realize the full potential of the new label [73] Other Important Information - The company is managing expenses diligently while preparing for a full-scale commercial launch next year [14] - The litigation case with Daiichi is ongoing, with a trial date set for April 15, 2024 [57] Q&A Session Summary Question: What is the outlook for gross-to-net trends in Q4? - Management noted typical seasonality in Q3 and expects continued improvement in gross-to-net trends over the longer term [19] Question: When could the milestone from the litigation case hit Esperion's balance sheet? - Management indicated that the milestone would not be recognized until early 2024, and they remain confident in the timeline [66] Question: How does the company plan to attract physicians interested in the drug? - Management mentioned that the team is unable to discuss new data until the label changes, which will help in expanding the population [22] Question: What is the typical patient profile for bempedoic acid? - The typical patient is on maximally tolerated statin therapy and not at their LDL-C goal, with a strong desire for primary prevention [80] Question: What are the approval rates for the therapies? - Approval rates have reached approximately 85% in commercial and Medicare, following presentations of CVOT data [83]

• On max tolerated statin Important Safety Information | --- | --- | |-------------------------------------|----------------------| | FY 2023 R&D Guidance | $100 - 110 Million | | FY 2023 SG&A Guidance | $125 - 135 Million | | FY 2023 Op Ex Guidance1 | $225 - 245 Million | | Q3 2023 Common Shares Outstanding 2 | 112.1 Million | © 2023 Esperion. All/Rights Reserved – Do not copy or distribute. 13 © 2023 Esperion. All Rights Reserved – Do not copy or distribute. Corporate Update • Filed Rule 12(c) motion, req ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12( ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President and Chief Executive Officer Eric Warren - Chief Commercial Officer Benjamin Halladay - Chief Financial Officer JoAnne Foody - Chief Medical Officer Betty Swartz - Chief Strategy Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham & Company Joseph Thome - Cowen Thomas Shrader - BTIG J ...

REACHING GOALS Retail Prescription Equivalents Y/Y • Acceptance of two late-breaker presentations at European Society of Cardiology 2023 in August CVOT © 2023 Esperion. All Rights Reserved – Do not copy or distribute. 7 © 2023 Esperion. All Rights Reserved – Do not copy or distribute. • Primary hyperlipidemia Forward-looking Statements & Disclosures © 2023 Esperion. All Rights Reserved – Do not copy or distribute. Business Update Sheldon Koenig, President and CEO $26M 4 Total Revenue +37% Y/Y +26% Robust Da ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President and Chief Executive Officer Eric Warren - Chief Commercial Officer Benjamin Halladay - Chief Financial Officer JoAnne Foody - Chief Medical Officer Betty Swartz - Chief Strategy Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham Jessica Fye - JPMorgan Jason Zemansky - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Financial Data and Key Metrics Changes - The company reported U.S. net product revenue of $15 million for Q4 2022, a 23% increase year-over-year, and $55.9 million for the full year 2022, up approximately 40% year-over-year [4][11] - Total revenue for Q4 2022 was $18.8 million, a 22% increase year-over-year, while total revenue for the full year 2022 decreased by 4% to $75.5 million due to a one-time milestone payment [11] - Cash, cash equivalents, and investment securities totaled $166.9 million as of December 31, 2022, down from $309.3 million a year earlier [6] Business Line Data and Key Metrics Changes - Royalty revenue for Q4 2022 was $2.3 million, up 188% year-over-year, and $6.5 million for the full year, an 81% increase year-over-year [6] - Combined royalty and partner revenue for Q4 2022 was $3.9 million, a 22% increase year-over-year, but decreased by 49% for the full year to $19.6 million due to a prior year milestone payment [7] Market Data and Key Metrics Changes - The partner Daiichi Sankyo reported strong growth for NILEMDO and NUSTENDI in Europe, with over 82,000 patients in November 2022 [5] Company Strategy and Development Direction - The company is focused on expanding patient access and improving prior authorization criteria while preparing for regulatory filings with the FDA and EMA in the first half of 2023 [1] - Plans are underway to scale the commercial organization and transition to a broader promotional approach following the anticipated positive results from the CLEAR Outcomes trial [106] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the positive impact of the CLEAR Outcomes trial on clinical management for patients at risk for cardiovascular disease [116] - The company is optimistic about achieving broader patient access and reimbursement improvements following recent formulary additions [109] Other Important Information - The company has reduced SG&A expenses by 41% year-over-year, reflecting cost management strategies implemented in 2021 [113] - The upcoming presentation of the CLEAR Outcomes trial results is expected to be a pivotal moment for the company, with significant implications for future growth [106] Q&A Session Summary Question: What is the divergence of the meaning of clinically meaningful between the investment community and the medical communities? - Management emphasized that clinically meaningful results are those that improve patient health and influence prescribing practices, highlighting the differentiation of their drugs [121] Question: How familiar are prescribing physicians with the benefits of hsCRP and glucose control? - Management acknowledged that awareness is lower than desired but noted that exposure to their current profile has had a favorable impact, with significant changes expected following the CVOT data release [80] Question: How is the company thinking about spending on sales moving forward? - Management indicated that while they have managed cash prudently, they are considering ramping up sales efforts in anticipation of increased demand following the CLEAR Outcomes data [64]